Eli Lilly and Company (LLY) — closed signal from March 26, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 24, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$895.00 – $920.00Entry zone — fair-value band
$914.03Published — price the day we called it
$1,060.27Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,117.26Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 57 days.
Peak price
$1,182.73
peak on June 8, 2026 — not a realized returnPeak gain
+29.4%
peak, from the publication priceWindow close
$1,117.26
end-of-window price, context onlyDays to target
57
Window
March 26, 2026 – June 24, 2026
The thesis — published March 26, 2026
Predicted growth
+16%
over the measurement windowTarget price
$1,060.27
the price the thesis aimed forEntry zone
$895.00 – $920.00
the fair-value band we waited forPrice at publication
$914.03
published March 26, 2026Confidence
80%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly delivered another strong quarter and its business stayed solid during the recent pullback. The shares have slipped under the short-term trend but the fundamentals and defensive position in healthcare suggest the stock looks like it is resetting rather than failing. This gives room to recover if market swings remain high.
Primary drivers
- Quarterly results showed continued strong demand for key drugs
- Healthcare stocks can hold up better when markets are volatile
- Recent pullback moved the stock below its short-term trend
- Management tone and earnings execution reinforce confidence
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.